ArticleEuropean journal of medical research2025
Association of GABRG2 gene polymorphisms with idiopathic generalized epilepsy in Egyptian children: a case-control study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ion channel gene signature for diagnosis and antifibrotic therapy in liver fibrosis.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe GABRG2 gene polymorphisms C588T and 3145G>A could be predictive genetic markers that trigger idiopathic generalized epilepsy (IGE) or predict pharmaco-resistance to antiseizure medications (ASMs).
methodsThis case‒control study enrolled 85 children, including 34 patients with IGE who were responsive to ASMs (responsive group), 30 patients with IGE who were resistant to ASMs (resistant group), and 21 healthy children (control group). All participants were assessed for the GABRG2 C588T and GABRG2 3145G>A gene polymorphisms via polymerase chain reaction (PCR).
resultsThe CC genotype of the GABRG2 polymorphism was the most commonly reported genotype. The CT and TT genotypes were more frequently associated with epileptic patients than with controls. The T allele and the T-included genotypes were more common among epileptic patients than controls. Regarding the GABRG2 _3145G>A polymorphism, the AG genotype was the most frequent among the study groups. The GG phenotype was more common among epileptic children than in controls. The G allele and G-included genotypes were significantly associated with epilepsy (p = 0.02), with a 3.2-fold higher risk of occurrence of epilepsy for the G allele carriers. A statistically insignificant difference in the distribution of different genotypes and C & T alleles of the GABRG2 C588T polymorphism was detected between the ASMs-responsive and the ASMs-resistant subgroups. However, the TT genotype was more common in the ASMs-resistant subgroup (10% vs. 3%). The GABRG2_3145G>A polymorphism appeared to be a prognostic determinant of ASMs responsiveness; the GG genotype was significantly associated with poor control of seizure activity (47% vs. 24%, p = 0.05). The G-included genotypes were significantly associated with ASMs resistance (76% vs. 53%, p = 0.05).
conclusionsThe T allele and TT genotype of the GABRG2 C588T gene were more common among patients with IGE, whereas the G allele and the GG genotype of the GABRG2 3145G>A gene may be significant predictors of ASMs resistance among IGE patients. Results validation in larger, multi-center studies across diverse populations is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.